共查询到5条相似文献,搜索用时 15 毫秒
1.
Anti‐HLA sensitization after kidney allograft nephrectomy: changes one year post‐surgery and beneficial effect of intravenous immunoglobulin 下载免费PDF全文
Marie Matignon Claire Leibler Olivier Moranne Laurent Salomon Dominique Charron Philippe Lang Christian Jacquelinet Caroline Suberbielle Philippe Grimbert 《Clinical transplantation》2016,30(6):731-740
The analysis of anti‐HLA sensitization at the time of and following allograft nephrectomy may help clinicians to define better both the indications for nephrectomy and preventive therapeutic strategies. We carried out a retrospective analysis of anti‐HLA antibodies in 63 clinically indicated nephrectomies (baseline and three and 12 months after) according to the time elapsed since transplantation (six months) and clinical background. An intervention study included 10 patients without donor‐specific antibodies (DSA) at the time of nephrectomy treated with high‐dose intravenous immunoglobulin (IVIG) (1.5 g/kg). Early nephrectomies were performed in 15 patients (24%). Among the late nephrectomies, 14 patients (22%) were asymptomatic and 34 (54%) had graft intolerance syndrome (GIS). At baseline, anti‐HLA sensitization was significantly lower in the early and late asymptomatic groups than in the GIS group, but increased considerably within the three months following surgery. In the group of 10 patients treated with IVIG, only the number of class I non‐DSA increased in the three months after surgery, whereas in the control group (N = 13), all anti‐HLA variables increased significantly. All patients undergoing a clinically indicated allograft nephrectomy become highly sensitized within the 12 months after surgery. In patients without DSA before nephrectomy, high doses of IVIG may prevent anti‐HLA sensitization. 相似文献
2.
De novo donor‐specific HLA antibodies after combined intestinal and vascularized composite allotransplantation — a retrospective study 下载免费PDF全文
Annemarie Weissenbacher Georgios Vrakas Mian Chen Srikanth Reddy Philip Allan Henk Giele Martin C.N.M Barnardo Anil Vaidya Peter J. Friend Susan V. Fuggle 《Transplant international》2018,31(4):398-407
Combining vascularized composite allotransplantation (VCA) with intestinal transplantation to achieve primary abdominal closure has become a feasible procedure. Besides facilitating closure, the abdominal wall can be used to monitor intestinal rejection. As the inclusion of a VCA raises the possibility of an enhanced alloimmune response, we investigated the incidence and clinical effect of de novo donor‐specific HLA antibodies (dnDSA) in a cohort of patients receiving an intestinal transplant with or without a VCA. The sequential clinical study includes 32 recipients of deceased donor intestinal and VCA transplants performed between 2008 and 2015; eight (25%) modified multivisceral transplants and 24 (75%) isolated small bowel transplants. A VCA was used in 18 (56.3%) cases. There were no episodes of intestinal rejection without VCA rejection. Fourteen patients (14 of 29; 48.3%) developed dnDSA. In the VCA group, fewer patients developed dnDSA; six of 16 (37.5%) VCA vs. eight of 13 (61.5%) non‐VCA. There was no statistically significant difference in one‐ and 3‐year overall graft survival stratified for the presence of dnDSA; P = 0.286. In the study, there is no evidence that the addition of a VCA increases the incidence of dnDSA formation compared to transplantation of the intestine alone. 相似文献
3.
Martina Koch Christian Gräser Anja Lehnhardt Jörg M. Pollok Nikolaus Kröger Murielle Verboom Friedrich Thaiss Thomas Eiermann Björn Nashan 《Transplant international》2013,26(8):e64-e68
Although donor‐specific lymphocytotoxic antibodies are regarded as a contraindication for kidney transplantation (KTx), the data available for liver or combined liver or kidney transplantation (cLKTx) are scarce. Here, we report a case of a highly sensitized young man receiving his sixth liver and second kidney graft. Multiple anti‐HLA antibodies were present at the time of transplantation. As a result of suspected antibody‐mediated graft damage, the patient was treated with rituximab, plasmapheresis, intravenous immunoglobulins, splenectomy, and bortezomib to decrease the antibody production. So far, patient and allograft survival has reached 4 years despite failure to achieve a permanent reduction of anti‐HLA antibodies, and particularly nondonor directed antibodies. 相似文献
4.
5.